Venus Remedies Ltd announced the receipt of the final anticipated milestone payment of Rs. 11 crore from Cipla Ltd, marking the successful completion of all anticipated commercial milestones agreed under the 2019 arrangement for its novel AMR-focused anti-infective in the Indian territory.

The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019 for marketing and distribution in India. Cumulatively, the product has delivered therapeutic benefits to over one million patients throughout its lifecycle. No serious drug-related adverse events have been reported in post-marketing experience, reflecting a favourable safety profile in real-world use.

Designed to address treatment gaps where conventional antibiotics often fail, this AMR targeted therapy has become an important option in hospital practice and stands as a significant example of indigenous innovation delivering sustained clinical impact in a highburden setting like India.

Commenting on the milestone, Saransh Chaudhary, President, Global Critical Care, Venus Remedies Ltd, and CEO, VMRC, said: "The receipt of this final anticipated milestone payment is more than a financial outcome; it is a strong validation of the long-term clinical and commercial relevance of our AMR-focused research. Seeing a home-grown anti-infective reach over a million patients while meeting all performance targets agreed with our partner is deeply encouraging for our teams.

For Venus Remedies and VMRC, this success reinforces our commitment to sustained innovation in AMR. Our pipeline includes differentiated antibacterial candidates such as VRP034 and MET-X, both granted QIDP designation by the US FDA, alongside ongoing work in surveillance and stewardship through programmes like GASAR and international data-sharing collaborations. We remain focused on developing scienti.fically robust, clinically meaningful .solutions that help preserve the effectiveness of antibiotics and improve outcomes for patients facing serious infections."

The company will continue to prioritize AMR as a core strategic area, combining innovation, evidence generation and responsible use frameworks to address one of the most urgent healthcare challenges of this century.